Total Payments
$21,016
2024 Payments
$678.81
Companies
18
Transactions
42
Medicare Patients
5,231
Medicare Billing
$1.5M
Payment Breakdown by Category
Consulting$17,508 (83.3%)
Travel$2,395 (11.4%)
Food & Beverage$960.77 (4.6%)
Education$152.78 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,508 | 7 | 83.3% |
| Travel and Lodging | $2,395 | 10 | 11.4% |
| Food and Beverage | $960.77 | 20 | 4.6% |
| Education | $152.78 | 5 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $10,857 | 10 | $0 (2024) |
| Incyte Corporation | $3,632 | 6 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $3,260 | 1 | $0 (2023) |
| Cardinal Health 414, LLC | $2,382 | 4 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $137.85 | 2 | $0 (2022) |
| Rigel Pharmaceuticals, Inc. | $133.94 | 1 | $0 (2024) |
| IsoRay, Inc | $108.72 | 1 | $0 (2018) |
| Roche Diagnostics Corporation | $101.29 | 1 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $86.24 | 1 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $69.44 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $678.81 | 3 | AstraZeneca Pharmaceuticals LP ($525.00) |
| 2023 | $9,649 | 10 | Incyte Corporation ($3,632) |
| 2022 | $154.67 | 3 | Regeneron Healthcare Solutions, Inc. ($118.24) |
| 2021 | $39.30 | 2 | Abbott Laboratories ($39.30) |
| 2019 | $2,264 | 4 | AstraZeneca Pharmaceuticals LP ($2,220) |
| 2018 | $5,775 | 12 | AstraZeneca Pharmaceuticals LP ($5,355) |
| 2017 | $2,456 | 8 | Cardinal Health 414, LLC ($2,382) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $133.94 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 07/29/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: BioOncology | ||||||
| 12/05/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,260.00 | General |
| Category: Oncology | ||||||
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| Category: Oncology | ||||||
| 09/19/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $209.15 | General |
| 09/19/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $50.53 | General |
| 06/02/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $98.05 | General |
| 06/02/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $18.44 | General |
| 05/25/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,818.00 | General |
| 04/21/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $386.97 | General |
| 04/21/2023 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $265.07 | General |
| 04/21/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $45.00 | General |
| 12/09/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $118.24 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2022 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Structural Heart | ||||||
| 01/13/2022 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Pacemakers | ||||||
| 05/17/2021 | Abbott Laboratories | MitraClip System (Device) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Structural Heart | ||||||
| 05/17/2021 | Abbott Laboratories | MitraClip System (Device) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Structural Heart | ||||||
| 11/22/2019 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 03/25/2019 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.96 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 12/26/2018 | Lilly USA, LLC | — | Education | In-kind items and services | $30.00 | General |
| 12/11/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: Oncology | ||||||
| 11/30/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $479.94 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 2,721 | 100,337 | $2.7M | $1.0M |
| 2022 | 36 | 1,748 | 35,744 | $702,370 | $248,979 |
| 2021 | 13 | 418 | 7,535 | $485,532 | $132,688 |
| 2020 | 10 | 344 | 23,274 | $269,436 | $70,380 |
Total Patients
5,231
Total Services
166,890
Medicare Billing
$1.5M
Procedure Codes
107
All Medicare Procedures & Services
107 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 23 | 6,120 | $391,680 | $206,896 | 52.8% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 25 | 43,780 | $350,240 | $205,539 | 58.7% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 12 | 2,150 | $313,900 | $136,271 | 43.4% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 22 | 4,050 | $324,000 | $136,219 | 42.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 38 | 4,490 | $534,310 | $117,689 | 22.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 3,500 | $119,000 | $36,595 | 30.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 176 | 434 | $84,630 | $26,186 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 125 | 239 | $74,807 | $24,900 | 33.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 13 | 3,860 | $119,660 | $21,971 | 18.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 82 | 178 | $79,566 | $21,853 | 27.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 142 | 200 | $42,400 | $14,789 | 34.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 37 | 26,520 | $53,040 | $10,469 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 65 | $27,235 | $9,750 | 35.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $25,800 | $7,955 | 30.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $23,136 | $6,792 | 29.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 88 | $17,336 | $6,127 | 35.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 63 | 63 | $19,782 | $5,277 | 26.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 223 | 539 | $8,085 | $4,469 | 55.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 190 | 418 | $14,212 | $4,267 | 30.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 222 | 540 | $12,420 | $4,058 | 32.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 33 | 112 | $11,200 | $2,905 | 25.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 200 | $14,600 | $2,559 | 17.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 33 | 89 | $8,722 | $2,418 | 27.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 23 | 111 | $6,882 | $2,112 | 30.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 56 | 145 | $9,860 | $2,072 | 21.0% |
About Manoj Agarwal, MD, MBA
Manoj Agarwal, MD, MBA is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700891900.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Manoj Agarwal, MD, MBA has received a total of $21,016 in payments from pharmaceutical and medical device companies, with $678.81 received in 2024. These payments were reported across 42 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($17,508).
As a Medicare-enrolled provider, Agarwal has provided services to 5,231 Medicare beneficiaries, totaling 166,890 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 107 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 07/29/2006
- Last Updated 01/31/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700891900
Products in Payments
- TAGRISSO (Drug) $7,575
- XPOVIO (Drug) $3,260
- IMFINZI (Biological) $2,498
- CALQUENCE (Drug) $525.00
- Rezlidhia (Drug) $133.94
- LIBTAYO (Biological) $118.24
- Brachytherapy Source (Device) $108.72
- TD BenchMark IHC/ISH and Special Stains Reagents (Device) $101.29
- VELCADE (Drug) $86.24
- Erleada (Drug) $69.44
- MitraClip System (Device) $39.30
- ADCETRIS (Biological) $36.71
- TASIGNA (Drug) $24.75
- IBRANCE (Drug) $23.97
- RYDAPT (Drug) $23.70
- Phesgo (Biological) $19.87
- PRALUENT (Biological) $19.61
- MITRACLIP (Device) $19.56
- MICRA (Device) $16.87
- ELCAELCA X-80 (Device) $13.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732